Free Trial
NASDAQ:CNSP

CNS Pharmaceuticals Q2 2024 Earnings Report

CNS Pharmaceuticals logo
$1.09 +0.05 (+4.81%)
Closing price 03:59 PM Eastern
Extended Trading
$1.07 -0.02 (-1.74%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CNS Pharmaceuticals EPS Results

Actual EPS
-$336.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

CNS Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CNS Pharmaceuticals Announcement Details

Quarter
Q2 2024
Time
N/A
Conference Call Date
Tuesday, August 13, 2024
Conference Call Time
6:00PM ET

Upcoming Earnings

CNS Pharmaceuticals' Q1 2025 earnings is scheduled for Wednesday, May 21, 2025, with a conference call scheduled on Wednesday, May 14, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

CNS Pharmaceuticals Earnings Headlines

CNS Pharmaceuticals sees cash runway into 1Q26
Trump’s Secret Weapon
Have you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.
CNS Pharmaceuticals announces primary analysis of berubicin in GBM
See More CNS Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CNS Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CNS Pharmaceuticals and other key companies, straight to your email.

About CNS Pharmaceuticals

CNS Pharmaceuticals (NASDAQ:CNSP), a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

View CNS Pharmaceuticals Profile

More Earnings Resources from MarketBeat